Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nutriband Inc (NTRB)

Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,868
  • Shares Outstanding, K 11,106
  • Annual Sales, $ 2,090 K
  • Annual Income, $ -5,490 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.99
  • Price/Sales 22.74
  • Price/Cash Flow N/A
  • Price/Book 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +475,814.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +13.64%
on 12/27/24
5.16 -18.02%
on 01/03/25
+0.09 (+2.17%)
since 12/13/24
3-Month
3.72 +13.64%
on 12/27/24
8.49 -50.18%
on 10/15/24
-3.68 (-46.52%)
since 10/11/24
52-Week
2.22 +90.54%
on 03/15/24
9.60 -55.91%
on 07/24/24
+1.33 (+45.86%)
since 01/12/24

Most Recent Stories

More News
Nutriband Issues Letter to Shareholders

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
Nutriband Extends Chinese Patent to Macao for its AVERSAâ„¢ Abuse Deterrent Transdermal Technology

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
Nutriband Inc. Reports Record Third Quarter Revenue and Advances AVERSAâ„¢ Fentanyl Development Plans

Nutriband Inc. reports record Q3 revenue and advances AVERSA Fentanyl development, targeting NDA submission in 2025.Quiver AI SummaryNutriband Inc. announced its third-quarter financial results for 2024,...

NTRB : 4.23 (+2.42%)
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversaâ„¢ Abuse Deterrent Transdermal Technology

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
LLY : 797.48 (-0.30%)
NVS : 99.27 (+0.19%)
TEVA : 20.44 (-2.39%)
AMRX : 7.72 (-3.14%)
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
LLY : 797.48 (-0.30%)
NVS : 99.27 (+0.19%)
TEVA : 20.44 (-2.39%)
AMRX : 7.72 (-3.14%)
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSAâ„¢ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology   Nutriband...

NTRB : 4.23 (+2.42%)
NTRBW : 1.2700 (-23.03%)
Nutriband (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium...

NTRB : 4.23 (+2.42%)

Business Summary

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company is engaged in developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. Nutriband...

See More

Key Turning Points

3rd Resistance Point 4.35
2nd Resistance Point 4.32
1st Resistance Point 4.28
Last Price 4.23
1st Support Level 4.21
2nd Support Level 4.18
3rd Support Level 4.14

See More

52-Week High 9.60
Fibonacci 61.8% 6.78
Fibonacci 50% 5.91
Fibonacci 38.2% 5.04
Last Price 4.23
52-Week Low 2.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar